New Novozymes exec to halt bleeding in struggling growth division

A priority for Novozymes Executive Vice President Tine Sejersgård Fanø is to halt the bleeding which has rendered the growth field of bioethanol a deep disappointment.
Photo: Novozymes/ PR
Photo: Novozymes/ PR

2017 will be a fateful year for Novozymes, with critical focus on restoring investor confidence in the company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading


See all jobs